8-KExhibits & Filings

WELLS FARGO & COMPANY/MN 8-K Report, Exhibit Filing (Nov 1, 2019)

Filed November 1, 2019For Securities:WFCWFC-PDWFC-PCWFC-PYWFC-PAWFC-PLWFCNPWFC-PZ

Summary

This Wells Fargo & Company (WFC) 8-K filing from November 1, 2019, primarily serves to provide legal documentation related to a specific debt issuance by its subsidiary, Wells Fargo Finance LLC. Specifically, it includes the legal opinion from Faegre Baker Daniels LLP regarding the 0.25% Equity Linked Notes due November 1, 2024, which are linked to the common stock of Bristol-Myers Squibb Company. These notes are fully and unconditionally guaranteed by Wells Fargo & Company. For investors, the key takeaway is that this filing is procedural and relates to a specific, pre-existing debt instrument. It does not represent a new financial performance announcement, a change in business strategy, or a material update on the company's overall financial health. The filing's significance lies in providing the necessary legal assurance for this particular note issuance, ensuring compliance and investor confidence in the guarantee provided by the parent company.

Key Highlights

  • 1Wells Fargo Finance LLC issued 0.25% Equity Linked Notes due November 1, 2024.
  • 2These Notes are linked to the common stock of Bristol-Myers Squibb Company.
  • 3Wells Fargo & Company (WFC) fully and unconditionally guarantees the Notes.
  • 4The primary purpose of this 8-K filing is to include the legal opinion of Faegre Baker Daniels LLP.
  • 5The filing relates to a Registration Statement on Form S-3 previously filed by Wells Fargo.
  • 6The form of the Note itself was previously filed in an October 31, 2019, 8-K.

Frequently Asked Questions

The main purpose of this filing is to formally submit the legal opinion from Faegre Baker Daniels LLP concerning the 0.25% Equity Linked Notes issued by Wells Fargo Finance LLC and the guarantee provided by Wells Fargo & Company.

While the filing pertains to an issuance of Medium-Term Notes, Series A, the form of the note was previously filed, and this 8-K primarily serves to provide the associated legal opinion. It is documentation for an existing or recently completed issuance, not necessarily a new strategic financing announcement.

The primary risk for Wells Fargo & Company is related to its guarantee of the notes. If the underlying performance of Bristol-Myers Squibb's stock does not meet the terms of the equity-linked notes, Wells Fargo may have obligations under its guarantee, though the specific terms of the linkage and guarantee would need to be reviewed in the full note documentation.

No, this filing does not contain information regarding Wells Fargo's financial performance. It is a legal and procedural document related to a specific debt instrument and its guarantee.